The prevalence of Alzheimer’s disease (AD) is increasing, therefore, identifying biomarkers to predict those vulnerable to AD is imperative. Type 2 diabetes (T2D) serves as an independent risk factor for AD. Early prediction of T2D patients who may be more susceptible to AD, so as to achieve early intervention, is of great significance to reduce the prevalence of AD.
Objective:
To establish periphery biomarkers that could predict conversion of T2D into pre-AD-like cognitive decline.
Methods:
A follow-up study was carried out from 159 T2D patients at baseline. The correlations of cognitive states (by MMSE score) with multi-periphery biomarkers, including APOE genotype, plasma amyloid-β level, platelet GSK-3β activity, and olfactory score were analyzed by logistic regression. ROC curve was used for establishing the prediction model. Additionally, MRI acquired from 38 T2D patients for analyzing the correlation among cognitive function, biomarkers and brain structure.
Results:
Compared with the patients who maintained normal cognitive functions during the follow-up period, the patients who developed MCI showed worse olfactory function, higher platelet GSK-3β activity, and higher plasma Aβ42/Aβ40 ratio. We conducted a predictive model which T2D patients had more chance of suffering from pre-AD-like cognitive decline. The MRI data revealed MMSE scores were positively correlated with brain structures. However, platelet GSK-3β activity was negatively correlated with brain structures.
Conclusions:
Elevated platelet GSK-3β activity and plasma Aβ42/Aβ40 ratio with reduced olfactory function are correlated with pre-AD-like cognitive decline in T2D patients, which used for predicting which T2D patients will convert into pre-AD-like cognitive decline in very early stage.
SunH, SaeediP, KarurangaS, et al.IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for and projections for 2045. Diabetes Res Clin Pract2022; 183: 109119.
3.
ReijmerYD, BrundelM, de BresserJ, et al.Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: A diffusion tensor imaging study. Diabetes Care2013; 36: 137–144.
4.
GeijselaersSLC, SepSJS, StehouwerCDA, et al.Glucose regulation, cognition, and brain MRI in type 2 diabetes: A systematic review. Lancet Diabetes Endocrinol2015; 3: 75–89.
5.
KoekkoekPS, KappelleLJ, van den BergE, et al.Cognitive function in patients with diabetes mellitus: Guidance for daily care. Lancet Neurol2015; 14: 329–340.
6.
PetersenRC, RobertsRO, KnopmanDS, et al.Mild cognitive impairment: Ten years later. Arch Neurol2009; 66: 1447–1455.
7.
PetersenRC, StevensJC, GanguliM, et al.Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2001; 56: 1133–1142.
8.
XiaoS, LiJ, TangM, et al.Methodology of China’s national study on the evaluation, early recognition, and treatment of psychological problems in the elderly: The China Longitudinal Aging Study (CLAS). Shanghai Arch Psychiatry2013; 25: 91–98.
9.
PetersenRC, LopezO, ArmstrongMJ, et al.Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018; 90: 126–135.
10.
ChenX, HanP, YuX, et al.Relationships between sarcopenia, depressive symptoms, and mild cognitive impairment in Chinese community-dwelling older adults. J Affect Disord2021; 286: 71–77.
11.
KandimallaR, ThirumalaVandReddyPH. Is Alzheimer’s disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis1863: 1078–1089.
12.
Andreu-ReinonME, HuertaJM, GavrilaD, et al.Incidence of dementia and associated factors in the EPIC-Spain Dementia Cohort. J Alzheimers Dis2020; 78: 543–555.
13.
de BruijnRF, BosMJ, PortegiesML, et al.The potential for prevention of dementia across two decades: The prospective, population-based Rotterdam Study. BMC Med2015; 13: 132.
14.
FrisonE, DufouilC, HelmerC, et al.Diabetes-associated dementia risk and competing risk of death in the Three-City Study. J Alzheimers Dis2019; 71: 1339–1350.
15.
LuchsingerJA, PaltaP, RipponB, et al.Pre-diabetes, but not type 2 diabetes, is related to brain amyloid in late middle-age. J Alzheimers Dis2020; 75: 1241–1252.
16.
ChatterjeeSandMudherA. Alzheimer’s disease and type 2 diabetes: A critical assessment of the shared pathological traits. Front Neurosci2018; 12: 383.
17.
MittalKandKatareDP. Shared links between type 2 diabetes mellitus and Alzheimer’s disease: A review. Diabetes Metab Syndr2016; 10: S144–S149.
18.
SankarSB, Infante-GarciaC, WeinstockLD, et al.Amyloid beta and diabetic pathology cooperatively stimulate cytokine expression in an Alzheimer’s mouse model. J Neuroinflammation2020; 17: 38.
19.
Ramos-RodriguezJJ, Jimenez-PalomaresM, Murillo-CarreteroMI, et al.Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer’s disease. Psychoneuroendocrinology2015; 62: 69–79.
20.
XuZP, YangSL, ZhaoS, et al.Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: A multicentre, retrospective, nested case-control study. EBioMedicine2016; 5: 105–113.
21.
LiuY, ZhangS, HeB, et al.Periphery biomarkers for objective diagnosis of cognitive decline in type 2 diabetes patients. Front Cell Dev Biol2021; 9: 752753.
22.
RiedelBC, ThompsonPMandBrintonRD. Age, APOE and sex: Triad of risk of Alzheimer’s disease. J Steroid Biochem Mol Biol2016; 160: 134–147.
23.
BrookmeyerR, JohnsonE, Ziegler-GrahamK, et al.Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement2007; 3: 186–191.
24.
LiuCC, LiuCC, KanekiyoT, et al.Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
25.
MaRCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia2018; 61: 1249–1260.
26.
LuchsingerJA, ReitzC, PatelB, et al.Relation of diabetes to mild cognitive impairment. Arch Neurol2007; 64: 570–575.
27.
van den BergE, ReijmerYD, de BresserJ, et al.A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia2010; 53: 58–65.
28.
LiX, SongDandLengSX. Link between type 2 diabetes and Alzheimer’s disease: From epidemiology to mechanism and treatment. Clin Interv Aging2015; 10: 549–560.
29.
StrachanMW, ReynoldsRM, MarioniRE, et al.Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol2011; 7: 108–114.
30.
BiesselsGJ, StaekenborgS, BrunnerE, et al.Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol2006; 5: 64–74.
31.
CukiermanT, GersteinHCandWilliamsonJD. Cognitive decline and dementia in diabetes– systematic overview of prospective observational studies. Diabetologia2005; 48: 2460–2469.
32.
StrachanMW, DearyIJ, EwingFM, et al.Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care1997; 20: 438–445.
33.
JansonJ, LaedtkeT, ParisiJE, et al.Increased risk of type 2 diabetes in Alzheimer disease. Diabetes2004; 53: 474–481.
34.
KronerZ. The relationship between Alzheimer’s disease and diabetes: Type 3 diabetes?Altern Med Rev2009; 14: 373–379.
35.
de la MonteSM. Type 3 diabetes is sporadic Alzheimers disease: Mini-review. Eur Neuropsychopharmacol2014; 24: 1954–1960.
36.
ArnoldSE, ArvanitakisZ, Macauley-RambachSL, et al.Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nat Rev Neurol2018; 14: 168–181.
37.
TakedaS, SatoN, Uchio-YamadaK, et al.Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A2010; 107: 7036–7041.
38.
WatsonGS, PeskindER, AsthanaS, et al.Insulin increases CSF Abeta42 levels in normal older adults. Neurology2003; 60: 1899–1903.
39.
Clodfelder-MillerBJ, ZmijewskaAA, JohnsonGV, et al.Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes2006; 55: 3320–3325.
40.
KeYD, DelerueF, GladbachA, et al.Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease. PLoS One2009; 4: e7917.
41.
ZhangY, HuangNQ, YanF, et al.Diabetes mellitus and Alzheimer’s disease: GSK-3beta as a potential link. Behav Brain Res2018; 339: 57–65.
42.
de la MonteSMandWandsJR.. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease. J Alzheimers Dis2006; 9: 167–181.
43.
LiXH, LvBL, XieJZ, et al.AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging2012; 33: 1400–1410.
44.
PetersenRC, SmithGE, WaringSC, et al.Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
45.
PetersenRC, DoodyR, KurzA, et al.Current concepts in mild cognitive impairment. Arch Neurol2001; 58: 1985–1992.
46.
BennettDA, WilsonRS, SchneiderJA, et al.Natural history of mild cognitive impairment in older persons. Neurology2002; 59: 198–205.
47.
PetersenRC. Mild cognitive impairment as a diagnostic entity. J Intern Med2004; 256: 183–194.
48.
AlbertMS, DeKoskyST, DicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 270–279.
49.
DuboisB, FeldmanHH, JacovaC, et al.Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol2010; 9: 1118–1127.
50.
PrestiaA, CaroliA, WadeSK, et al.Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement2015; 11: 1191–1201.
51.
QuZS, TianQ, ZhouXW, et al.[Alteration of beta-amyloid and glutamate transporter in the brain of diabetes rats and the underlying mechanism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2005; 27: 708–711.
52.
DuLL, ChaiDM, ZhaoLN, et al.AMPK activation ameliorates Alzheimer’s disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer’s disease model in rats. J Alzheimers Dis2015; 43: 775–784.
53.
DuLL, XieJZ, ChengXS, et al.Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr)2014; 36: 613–623.
54.
Baglietto-VargasD, ShiJ, YaegerDM, et al.Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev2016; 64: 272–287.
55.
de la MonteSM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res2012; 9: 35–66.
56.
YangYandSongW. Molecular links between Alzheimer’s disease and diabetes mellitus. Neuroscience2013; 250: 140–150.
57.
JungHJ, ShinISandLeeJE. Olfactory function in mild cognitive impairment and Alzheimer’s disease: A meta-analysis. Laryngoscope2019; 129: 362–369.
58.
DevanandDP, LiuX, TabertMH, et al.Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry2008; 64: 871–879.
59.
DjordjevicJ, Jones-GotmanM, De SousaK, et al.Olfaction in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging2008; 29: 693–706.
60.
Lafaille-MagnanME, PoirierJ, EtienneP, et al.Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology2017; 89: 327–335.
61.
MarinC, VilasD, LangdonC, et al.Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep2018; 18: 42.
62.
HuB, GengCandHouXY. Oligomeric amyloid-beta peptide disrupts olfactory information output by impairment of local inhibitory circuits in rat olfactory bulb. Neurobiol Aging2017; 51: 113–121.
63.
RisacherSL, TallmanEF, WestJD, et al.Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. Alzheimers Dement (Amst)2017; 9: 57–66.
64.
JimenezA, Organista-JuarezD, Torres-CastroA, et al.Olfactory dysfunction in diabetic rats is associated with miR-146a overexpression and inflammation. Neurochem Res2020; 45: 1781–1790.
